CommentaryKDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Section snippets
KDIGO Guideline Process
The KDIGO transplant guideline concentrated mainly on aspects of transplant care most important to this population in the posttransplant period, such as immunosuppression, infection, malignancy, and cardiovascular care. The guidelines do not address pretransplant evaluation or issues related to patients returning to dialysis therapy with a failed allograft. The target audience for the guideline is physicians, coordinators, pharmacists, and other medical professionals who directly or indirectly
KDOQI Process for Interpretation of the KDIGO Guideline in the Care of US Transplant Patients
Differences in target population, individual patient immunologic risk, prevalence of concomitant diseases (such as diabetes mellitus), availability of resources, and systems of payment must all be considered in interpreting global recommendations to specific regions. The following commentaries on the KDIGO guideline represent the consensus of a work group convened by KDOQI to evaluate the relevance and applicability of the guideline to US patients and practices. It is beyond the scope of our
KDIGO Recommendations in Chapter 1: Induction Therapy
- 1.1:
We recommend starting a combination of immunosuppressive medications before, or at the time of, kidney transplantation. (1A)
- 1.2:
We recommend including induction therapy with a biologic agent as part of the initial immunosuppressive regimen in KTRs. (1A)
- 1.2.1:
We recommend that an IL2-RA [interleukin-2 receptor antagonist] be the firstline induction therapy. (1B)
- 1.2.2:
We suggest using a lymphocyte-depleting agent, rather than an IL2-RA, for KTRs at high immunologic risk. (2B)
KDOQI Rationale and Commentary
It clearly is important to start
Summary of Commentary on Section I: Immunosuppression
KDIGO Recommendations in Chapter 8: Monitoring Kidney Allograft Function
- 8.1:
We suggest measuring urine volume (2C):
- ∙
Every 1-2 hours for at least 24 hours after transplantation (2D);
- ∙
Daily until graft function is stable. (2D)
- 8.2:
We suggest measuring urine protein excretion, (2C) at least:
- ∙
Once in the first month to determine a baseline (2D);
- ∙
Every 3 months during the first year (2D);
- ∙
Annually, thereafter. (2D)
- 8.3:
We recommend measuring serum creatinine, (1B) at least:
- ∙
Daily for 7 days or until hospital discharge, whichever occurs sooner (2C);
- ∙
2-3 times per week for weeks 2-4 (2C);
- ∙
Summary of Commentary on Section II: Graft Monitoring and Infections
KDIGO Recommendations in Chapter 15: Diabetes Mellitus
- 15.1:
Screening for New-Onset Diabetes after Transplantation
- 15.1.1:
We recommend screening all nondiabetic KTRs with fasting plasma glucose, oral glucose tolerance testing, and/or HbA1c (1C) at least:
- ∙
weekly for 4 weeks (2D);
- ∙
every 3 months for 1 year (2D);
- ∙
and annually, thereafter. (2D)
- 15.1.2:
We suggest screening for NODAT with fasting glucose, oral glucose tolerance testing, and/or after starting, or substantially increasing the dose, of CNIs, mTORi, or corticosteroids. (2D)
- 15.2:
Managing NODAT or Diabetes Present at
Summary of Commentary on Section III: CVD
KDIGO Recommendations in Chapter 18: Cancer of the Skin and Lip
- 18.1:
We recommend that KTRs, especially those who have fair skin, live in high sun-exposure climates, have occupations requiring sun exposure, have had significant sun exposure as a child, or have a history of skin cancer, be told that their risk of skin and lip cancer is very high. (1C)
- 18.2:
We recommend that KTRs minimize life-long sun exposure and use appropriate ultraviolet light blocking agents. (1D)
- 18.3:
We suggest that adult KTRs perform skin and lip self-examinations and report new lesions to a
Summary of Commentary on Section IV: Malignancy
KDIGO Recommendations in Chapter 21: Transplant Bone Disease
- 21.1:
In patients in the immediate post kidney transplant period, we recommend measuring serum calcium and phosphorus at least weekly, until stable. (1B)
- 21.2:
In patients after the immediate post kidney transplant period, it is reasonable to base the frequency of monitoring serum calcium, phosphorus and PTH on the presence and magnitude of abnormalities, and the rate of progression of CKD. (Not Graded)
- 21.2.1:
Reasonable monitoring intervals would be (Not Graded):
- ∙
In CKD stages 1–3T, for serum calcium and
Summary of Commentary on Section V: Other Complications
Research
At the end of each section, members of the KDIGO work group made several suggestions for areas of future research. Our KDOQI work group agreed with the critical importance of research in these areas to create evidence upon which future recommendations and guidelines can be based.
Conclusion
The new KDIGO guideline for the care of kidney transplant patients are broad in scope and should serve as guide for all clinicians caring for KTRs, including transplant clinicians, nephrologists, nurses, and fellows in training. Our KDOQI work group concurred with many of the KDIGO recommendations except in some important areas related to immunosuppression. Decisions about immunosuppression in the United States are largely made by transplant centers and are dependent in part on the specific
Acknowledgements
Guideline recommendations included in this article originally were published in the American Journal of Transplantation3 and were reproduced with permission from KDIGO.
We thank Robert Harland, MD, for input on the applicability of the KDIGO guideline for US KTRs; Drs Jeffrey Stein and Oscar Colegio for input on the pediatric and skin cancer recommendations; Drs Jeffrey Berns and Michael Rocco for careful review of this manuscript; and Anita Viliusis and Kerry Willis from the National Kidney
References (89)
- et al.
Kidney and pancreas transplant in the United States, 1998-2007: access for patients with diabetes and end stage renal disease
Am J Transplant
(2009) - et al.
Kidney and pancreas transplantation in the United States, 1996-2005
Am J Transplant
(2007) - et al.
Calcineurin inhibitor minimization in the Symphony Study: observational results 3 years after transplantation
Am J Transplant
(2009) - et al.
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study
Am J Transplant
(2009) - et al.
AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients
Am J Transplant
(2009) - et al.
Fixed or controlled-dose mycophenolate mofetil with standard or reduced-dose calcineurin inhibitors: the Opticept trial
Am J Transplant
(2009) - et al.
Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study
Am J Transplant
(2007) - et al.
The role of antibodies in transplantation
Transpl Rev
(2009) - et al.
Monitoring and treating posttransplant human leukocyte antigen antibodies
Hum Immunol
(2009) - et al.
Definition and classification of Chronic Kidney Disease: Improving Global Outcomes (KDIGO)
Kidney Int
(2005)
Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients?
Transplant Proc
Protocol biopsies in renal transplantation: insights into patient management and pathogenesis
Am J Transplant
: Diagnosing rejection in renal transplants: a comparison of molecular- and histolopathology-based approaches
Am J Transplant
Recurrent glomerulonephritis after kidney transplantation
Am J Transplant
Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk
Kidney Int
Nonadherence consensus conference summary report
Am J Transplant
Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients
Am J Transplant
Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial
Am J Transplant
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes
Am J Transplant
Performance of tests for latent tuberculosis in different groups of immunocompromised patients
Chest
Diabetes mellitus after kidney transplantation in the United States
Am J Transplant
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients
Am J Transplant
Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally
Am J Transplant
New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation
Kidney Int
Interaction of cyclosporine and FK506 with diuretics in transplant patients
Kidney Int
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
Am J Transplant
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus
Am J Transplant
Clinical epidemiology of cardiovascular disease in chronic renal disease
Am J Kidney Dis
Use of cardioprotective medications in kidney transplant recipients
Am J Transplant
Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey
Am J Gastroenterol
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Lancet
The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling
Kidney Int
Vitamin D status in renal transplant patients
Am J Transplant
Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials
Am J Kidney Dis
Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density
Am J Transplant
Anemia after kidney transplantation is not completely explained by reduced kidney function
Am J Kidney Dis
Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials
J Pediatr
Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation
Am J Transplant
The burden of kidney disease: improving global outcomes
Kidney Int
KDIGO clinical practice guidelines for the care of kidney transplant recipients
Am J Transplant
KDIGO clinical practice guideline for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease
Kidney Int Suppl
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)
Kidney Int Suppl
Reduced exposure to calcineurin inhibitors in renal transplantation
N Engl J Med
Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation
Transplantation
Cited by (60)
Role of Renal Venous Oxygen Pressure for Renal Function Monitoring After Related Living-Donor Kidney Transplantation: Cohort Study
2024, Transplantation ProceedingsThe impact of induction therapy in low-immunological risk kidney transplant recipients regardless of HLA matching
2023, Transplant ImmunologyCitation Excerpt :The authors recommended the use of interleukin 2 receptor antagonist (IL2-RA) as a first-line induction therapy in low immunological risk kidney transplanted recipients (KTRs) (Grade 1B). Besides, lymphocyte-depleting agents like rabbit anti-thymocyte globulin (rATG) are used for induction therapy in high immunologic risk patients (Grade 2B) [5,6]. In 2010, Cochrane Collaboration performed a meta-analysis of randomized control trials in low-risk KTRs to compare the efficacy of IL2-RA and Thymoglobulin.
Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis
2023, The Lancet Child and Adolescent HealthProtocol for the AKT-MP trial: Access to Kidney Transplantation in Minority Populations
2022, Contemporary Clinical Trials Communications
Originally published online as doi:10.1053/j.ajkd.2010.04.010 on July 2, 2010.
Reprint requests to Kerry Willis, PhD, National Kidney Foundation, 30 E 33rd St, New York, NY 10016. E-mail: [email protected]